Deferred Tax Assets, Operating Loss Carryforwards of NEXIEN BIOPHARMA, INC. from 30 Jun 2017 to 30 Jun 2024

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
NEXIEN BIOPHARMA, INC. quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD history and change rate from 30 Jun 2017 to 30 Jun 2024.
  • NEXIEN BIOPHARMA, INC. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending 30 Jun 2024 was $726,195, a 5.4% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Change (%)

NEXIEN BIOPHARMA, INC. Quarterly Deferred Tax Assets, Operating Loss Carryforwards (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2024 $726,195 +$37,272 +5.4% 30 Jun 2024 10-K 22 Oct 2024 2024 FY
Q2 2023 $688,923 +$38,232 +5.9% 30 Jun 2023 10-K 22 Oct 2024 2024 FY
Q2 2022 $650,691 +$33,370 +5.4% 30 Jun 2022 10-K 28 Sep 2023 2023 FY
Q2 2021 $617,321 +$52,348 +9.3% 30 Jun 2021 10-K 28 Sep 2022 2022 FY
Q2 2020 $564,973 +$94,745 +20% 30 Jun 2020 10-K 12 Oct 2021 2021 FY
Q2 2019 $470,228 -$98,506 -17% 30 Jun 2019 10-K 28 Sep 2020 2020 FY
Q2 2018 $568,734 +$497,789 +702% 30 Jun 2018 10-K 30 Sep 2019 2019 FY
Q2 2017 $70,945 30 Jun 2017 10-K 28 Sep 2018 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.